This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

This study has been terminated.
(The study was terminated due to results in another study (NCT00878501).)
Information provided by:
AstraZeneca Identifier:
First received: September 9, 2009
Last updated: December 21, 2009
Last verified: December 2009
The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

Condition Intervention Phase
Pain Neuropathic Pain Drug: AZD1386 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change from baseline in NRS pain (12 h-recall) [ Time Frame: Morning and evening 12 hour recall ]

Secondary Outcome Measures:
  • Response rate, defined as any of the following:NRS (12 h recall) reduced by 30% compared to baseline and NRS (12 h recall) reduced by 50% compared to baseline [ Time Frame: Morning and evening 12 hour recall ]
  • Response rate, defined as any of the following: At least "much improved" on Patient Global Impression of Change global and at least "much improved" on PGIC pain [ Time Frame: Day 8, 15 and 22 ]
  • Response rate, defined as any of the following: Change from baseline in Brief Pain Inventory Short Form and Change from baseline in Pain Quality Assessment Scale [ Time Frame: Day 1 and 22 ]

Estimated Enrollment: 90
Study Start Date: September 2009
Estimated Study Completion Date: February 2010
Arms Assigned Interventions
Experimental: 1 Drug: AZD1386
90 mg, capsules, oral, during 3 weeks
Placebo Comparator: 2 Drug: Placebo
capsules, oral, during 3 weeks


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with painful symptoms due to neuropathic pain
  • Provision of signed informed consent
  • Non pregnant females

Exclusion Criteria:

  • Other pain conditions that may confound assessment of neuropathic pain, as judged by the investigator
  • History, and/or presence of somatic disease, which may interfere with the objectives of the study as judged by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00976534

Canada, Alberta
Research Site
Calgary, Alberta, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Toronto, Ontario, Canada
Research Site
Alborg, Denmark
Research Site
Arhus C, Denmark
Research Site
Boulogne Billancourt, France
Research Site
Clermont Ferrand, France
Research Site
Nice, France
United Kingdom
Research Site
Bradford, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Sponsors and Collaborators
Study Director: Richard L Leff, md AstraZeneca R&D Wilmington, USA
Study Chair: Rolf Karlsten, MD AstraZeneca R&D Södertälje, Sweden
  More Information

Responsible Party: AstraZeneca Pharmaceuticals, AstraZeneca Identifier: NCT00976534     History of Changes
Other Study ID Numbers: D5090C00018
Study First Received: September 9, 2009
Last Updated: December 21, 2009

Keywords provided by AstraZeneca:
Analgesic effect
Peripheral Neuropathic pain
Posttraumatic Neuralgia (PTN)
Postherpetic Neuralgia (PHN)

Additional relevant MeSH terms:
Neuralgia, Postherpetic
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms processed this record on August 17, 2017